Referenser

  1. van Os J, Kapur S. Schizophrenia. Lancet. 2009;374(9690):635-45.

  2. Cardno AG, Marshall EJ, Coid B, Macdonald AM, Ribchester TR, Davies NJ, et al. Heritability estimates for psychotic disorders: the Maudsley twin psychosis series. Arch Gen Psychiatry. 1999;56(2):162-8.

  3. Howes OD, McDonald C, Cannon M, Arseneault L, Boydell J, Murray RM. Pathways to schizophrenia: the impact of environmental factors. Int J Neuropsychopharmacol. 2004;7 Suppl 1:S7-s13.

  4. Kelly BD, Feeney L, O'Callaghan E, Browne R, Byrne M, Mulryan N, et al. Obstetric adversity and age at first presentation with schizophrenia: evidence of a dose-response relationship. Am J Psychiatry. 2004;161(5):920-2.

  5. Richetto J, Meyer U. Epigenetic Modifications in Schizophrenia and Related Disorders: Molecular Scars of Environmental Exposures and Source of Phenotypic Variability. Biol Psychiatry. 2021;89(3):215-26.

  6. Tsapakis E-M, Guillin O, Murray RM. Does dopamine sensitization underlie the association between schizophrenia and drug abuse? Current Opinion in Psychiatry. 2003;16:S45-S52.

  7. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. Bmj. 2002;325(7374):1199.

  8. Joy CB, Adams CE, Lawrie SM. Haloperidol versus placebo for schizophrenia. Cochrane Database Syst Rev. 2006(4):Cd003082.

  9. Fleischhacker WW, Cetkovich-Bakmas M, De Hert M, Hennekens CH, Lambert M, Leucht S, et al. Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry. 2008;69(4):514-9.

  10. Osby U, Correia N, Brandt L, Ekbom A, Sparén P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res. 2000;45(1-2):21-8.

  11. Strauss GP, Bartolomeo LA, Harvey PD. Avolition as the core negative symptom in schizophrenia: relevance to pharmacological treatment development. NPJ Schizophr. 2021;7(1):16.

  12. Honea R, Crow TJ, Passingham D, Mackay CE. Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. Am J Psychiatry. 2005;162(12):2233-45.

  13. American Psychiatric Association. Diagnostic and statistical manual of mental disorders 5th ed. Washington, DC2013.

  14. National Collaborating Centre for Mental H. National Institute for Health and Clinical Excellence: Guidance.  Psychosis and Schizophrenia in Adults: Treatment and Management: Updated Edition 2014. London: National Collaborating Centre for Mental Health, 2014.; 2014.

  15. Hjorthøj C, Stürup AE, McGrath JJ, Nordentoft M. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry. 2017;4(4):295-301.

  16. Svenska Psykiatriska Föreningen. Schizofreni - kliniska riktlinjer för utredning och behandling. Laurell BW, editor. Stockholm: Svenska Psykiatriska Föreningen; 2009. 1-126 p.

  17. Larson FV, Wagner AP, Jones PB, Tantam D, Lai MC, Baron-Cohen S, et al. Psychosis in autism: comparison of the features of both conditions in a dually affected cohort. Br J Psychiatry. 2017;210(4):269-75.

  18. Wearne D, Genetti A. Pseudohallucinations versus hallucinations: wherein lies the difference? Australas Psychiatry. 2015;23(3):254-7.

  19. Whiting D, Gulati G, Geddes JR, Fazel S. Association of Schizophrenia Spectrum Disorders and Violence Perpetration in Adults and Adolescents From 15 Countries: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2022;79(2):120-32.

  20. Carlborg A, Winnerbäck K, Jönsson EG, Jokinen J, Nordström P. Suicide in schizophrenia. Expert Rev Neurother. 2010;10(7):1153-64.

  21. Läkemedelsverket. Läkemedel vid schizofreni - behandlings­rekommendation Uppsala: Läkemedelsverket; 2013 [Available from: https://www.lakemedelsverket.se/sv/behandling-och-forskrivning/behandlingsrekommendationer/sok-behandlingsrekommendationer/lakemedel-vid-schizofreni---behandlingsrekommendation

  22. Solmi M, Fornaro M, Ostinelli EG, Zangani C, Croatto G, Monaco F, et al. Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. World Psychiatry. 2020;19(2):214-32.

  23. Tang Y, Wu Y, Li X, Hao Q, Deng W, Yue W, et al. Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial. Curr Neuropharmacol. 2023;21(2):424-36.

  24. Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939-51.

  25. Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374(9690):620-7.

  26. Socialstyrelsen. Nationella riktlinjer för vård och stöd vid schizofreni och schizofreniliknande tillstånd – Stöd för styrning och ledning Stockholm 2018 [Available from: https://www.socialstyrelsen.se/kunskapsstod-och-regler/regler-och-riktlinjer/nationella-riktlinjer/riktlinjer-och-utvarderingar/schizofreni/

  27. Galling B, Vernon JA, Pagsberg AK, Wadhwa A, Grudnikoff E, Seidman AJ, et al. Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia. Acta Psychiatr Scand. 2018;137(3):187-205.

  28. Barber S, Olotu U, Corsi M, Cipriani A. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. Cochrane Database Syst Rev. 2017;3(3):Cd006324.

  29. Kantrowitz JT. Managing Negative Symptoms of Schizophrenia: How Far Have We Come? CNS Drugs. 2017;31(5):373-88.

  30. Lian L, Kim DD, Procyshyn RM, Fredrikson DH, Cázares D, Honer WG, et al. Efficacy of long-acting injectable versus oral antipsychotic drugs in early psychosis: A systematic review and meta-analysis. Early Interv Psychiatry. 2022;16(6):589-99.

  31. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60(1):82-91.

  32. Desai Boström AE, Andersson P, Rask-Andersen M, Jarbin H, Lundberg J, Jokinen J. Regional clozapine, ECT and lithium usage inversely associated with excess suicide rates in male adolescents. Nat Commun. 2023;14(1):1281.

  33. Tiihonen J, Wahlbeck K, Lönnqvist J, Klaukka T, Ioannidis JP, Volavka J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. Bmj. 2006;333(7561):224.

  34. Huybrechts KF, Gerhard T, Crystal S, Olfson M, Avorn J, Levin R, et al. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. Bmj. 2012;344:e977.

  35. Sendt KV, Tracy DK, Bhattacharyya S. A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders. Psychiatry Res. 2015;225(1-2):14-30.

  36. Kardas P, Lewek P, Matyjaszczyk M. Determinants of patient adherence: a review of systematic reviews. Front Pharmacol. 2013;4:91.

  37. Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry. 2003;60(12):1228-35.

  38. Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS, et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry. 2009;166(6):675-82.

  39. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-23.

  40. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60(6):553-64.

  41. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085-97.

  42. Msghina M. LN. Antipsykotiska läkemedel väljs bäst efter biverkningsprofil. Läkartidningen. 2009;106(4):2841-6.

  43. Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science. 1975;188(4194):1217-9.

  44. Gerolymos C, Barazer R, Yon DK, Loundou A, Boyer L, Fond G. Drug Efficacy in the Treatment of Antipsychotic-Induced Akathisia: A Systematic Review and Network Meta-Analysis. JAMA Netw Open. 2024;7(3):e241527.

  45. Caroff SN. A new era in the diagnosis and treatment of tardive dyskinesia. CNS Spectr. 2022:4-14.

  46. Lambiase PD, de Bono JP, Schilling RJ, Lowe M, Turley A, Slade A, et al. British Heart Rhythm Society Clinical Practice Guidelines on the Management of Patients Developing QT Prolongation on Antipsychotic Medication. Arrhythm Electrophysiol Rev. 2019;8(3):161-5.

  47. Taipale H, Solmi M, Lähteenvuo M, Tanskanen A, Correll CU, Tiihonen J. Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland. Lancet Psychiatry. 2021;8(10):883-91.

  48. Jiang Q, Li T, Zhao L, Sun Y, Mao Z, Xing Y, et al. Treatment of antipsychotic-induced hyperprolactinemia: an umbrella review of systematic reviews and meta-analyses. Front Psychiatry. 2024;15:1337274.

  49. Svenska Psykiatriska Föreningen SFfBoU, Svensk Förening för Allmänmedicin, Svensk Förening för Diabetologi, Svensk Internmedicinsk Förening, Svenska Cardiologföreningen, Svensk Förening för Obesitasforskning,. Kliniska riktlinjer; Att förebygga och handlägga metabol risk hos patienter med allvarlig psykisk sjukdom Göteborg: Svenska Psykiatriska Föreningen; 2009 [Available from: https://www.svenskpsykiatri.se/wp-content/uploads/2017/02/SPF-kliniska-riktlinjer-om-metabol-risk.pdf

  50. Björkhem-Bergman L, Asplund AB, Lindh JD. Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: a systematic review and meta-analysis. J Psychopharmacol. 2011;25(3):299-305.

Föregående sida
För vidare läsning

Nästa sida
Tillbaka till kapitlets första sida